Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bicara Therapeutics Inc.BCAX · Entity 4673 | Chief Medical Officer | April 27, 2026 | April 28, 2026 |
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Chief Medical Officer | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bicara Therapeutics Inc.
Report date April 27, 2026 · Filed April 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,286 |
Ending reported balance
After 2026-04-27 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-27 · Exercise / conversion · Acquired 5,500 · Balance 60,786 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Row 2 · 2026-04-27 · Sale · Disposed 5,500 · Balance 55,286 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.51 to $23.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.79 · Expires 2023-08-08 | Direct | 41,913 |
Reported balance
After 2026-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-27 · Exercise / conversion · Disposed 5,500 · Balance 41,913 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.51 to $23.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.
PLIANT THERAPEUTICS, INC.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 · Expires 2036-10-01 | Direct | 575,000 |
Reported balance
After 2026-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 575,000 · Balance 575,000 F1: Twenty-five percent (25%) of the shares subject to such option vest and become exercisable on September 30, 2027, and the remaining seventy-five percent (75%) of the shares subject to the option vest and become exercisable in substantially equal installments thereafter on each monthly anniversary of September 30, 2027 (or if there is no corresponding day in any such month, on the last day of each month) over three (3) years, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent (25%) of the shares subject to such option vest and become exercisable on September 30, 2027, and the remaining seventy-five percent (75%) of the shares subject to the option vest and become exercisable in substantially equal installments thereafter on each monthly anniversary of September 30, 2027 (or if there is no corresponding day in any such month, on the last day of each month) over three (3) years, subject to the Reporting Person's continuous service to the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:20 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 575,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001746473-26-000117 · wk-form4_1790972430.xml · derivative · entry 1 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,000 Underlying: Common Stock · 575,000 shares Expires 2036-10-01 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to such option vest and become exercisable on September 30, 2027, and the remaining seventy-five percent (75%) of the shares subject to the option vest and become exercisable in substantially equal installments thereafter on each monthly anniversary of September 30, 2027 (or if there is no corresponding day in any such month, on the last day of each month) over three (3) years, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| April 27, 2026 Filed Apr 28, 2026 23:49 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,500 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-028054 · wk-form4_1777420165.xml · derivative · entry 3 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,913 Underlying: Common Stock · 5,500 shares Expires 2023-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| April 27, 2026 Filed Apr 28, 2026 23:49 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 5,500 | $22.88 | $125,830.10 |
DisclosureSEC source: 0001628280-26-028054 · wk-form4_1777420165.xml · nonDerivative · entry 2 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,286 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.51 to $23.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| April 27, 2026 Filed Apr 28, 2026 23:49 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 5,500 | $3.79 | $20,843.90 |
DisclosureSEC source: 0001628280-26-028054 · wk-form4_1777420165.xml · nonDerivative · entry 1 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| March 25, 2026 Filed Mar 26, 2026 23:21 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,500 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-021543 · wk-form4_1774567271.xml · derivative · entry 3 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,413 Underlying: Common Stock · 5,500 shares Expires 2023-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 25, 2026 Filed Mar 26, 2026 23:21 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 5,500 | $18.95 | $104,229.40 |
DisclosureSEC source: 0001628280-26-021543 · wk-form4_1774567271.xml · nonDerivative · entry 2 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,286 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.55 to $19.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 25, 2026 Filed Mar 26, 2026 23:21 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 5,500 | $3.79 | $20,843.90 |
DisclosureSEC source: 0001628280-26-021543 · wk-form4_1774567271.xml · nonDerivative · entry 1 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 00:06 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,300 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-015419 · wk-form4_1772755592.xml · derivative · entry 6 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,913 Underlying: Common Stock · 16,300 shares Expires 2023-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 00:06 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 16,300 | $18.52 | $301,920.01 |
DisclosureSEC source: 0001628280-26-015419 · wk-form4_1772755592.xml · nonDerivative · entry 4 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,286 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.45 to $18.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 00:06 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 16,300 | $3.79 | $61,773.74 |
DisclosureSEC source: 0001628280-26-015419 · wk-form4_1772755592.xml · nonDerivative · entry 3 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 00:06 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-015419 · wk-form4_1772755592.xml · derivative · entry 5 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,213 Underlying: Common Stock · 200 shares Expires 2023-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 00:06 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 200 | $18.45 | $3,690.00 |
DisclosureSEC source: 0001628280-26-015419 · wk-form4_1772755592.xml · nonDerivative · entry 2 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,286 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 00:06 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 200 | $3.79 | $757.96 |
DisclosureSEC source: 0001628280-26-015419 · wk-form4_1772755592.xml · nonDerivative · entry 1 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:36 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $16.76 | $0.00 |
DisclosureSEC source: 0001628280-26-005479 · wk-form4_1770240967.xml · derivative · entry 1 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 26, 2025 Filed Dec 29, 2025 22:10 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,789 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-25-059035 · wk-form4_1767046215.xml · derivative · entry 2 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,987 Underlying: Common Stock · 19,789 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares underlying this option vested on July 24, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 26, 2025 Filed Dec 29, 2025 22:10 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 19,789 | $3.79 | $74,996.35 |
DisclosureSEC source: 0001628280-25-059035 · wk-form4_1767046215.xml · nonDerivative · entry 1 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an ISO exercise and hold to acquire and retain direct share ownership of the issuer. Read SEC document |
| November 25, 2025 Filed Nov 25, 2025 23:39 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 906 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0002034679-25-000006 · wk-form4_1764113985.xml · derivative · entry 9 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,413 Underlying: Common Stock · 906 shares Expires 2023-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F4 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| November 25, 2025 Filed Nov 25, 2025 23:39 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,594 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0002034679-25-000006 · wk-form4_1764113985.xml · derivative · entry 8 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,776 Underlying: Common Stock · 4,594 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · derivative.exercise_date: 25% of the shares underlying this option vested on July 24, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| November 25, 2025 Filed Nov 25, 2025 23:39 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 906 | $18.84 | $17,071.21 |
DisclosureSEC source: 0002034679-25-000006 · wk-form4_1764113985.xml · nonDerivative · entry 6 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,497 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.68 to $19.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| November 25, 2025 Filed Nov 25, 2025 23:39 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 906 | $3.79 | $3,433.56 |
DisclosureSEC source: 0002034679-25-000006 · wk-form4_1764113985.xml · nonDerivative · entry 5 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| November 25, 2025 Filed Nov 25, 2025 23:39 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 4,594 | $18.84 | $86,561.99 |
DisclosureSEC source: 0002034679-25-000006 · wk-form4_1764113985.xml · nonDerivative · entry 4 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,497 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.68 to $19.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| November 25, 2025 Filed Nov 25, 2025 23:39 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 4,594 | $3.79 | $17,410.34 |
DisclosureSEC source: 0002034679-25-000006 · wk-form4_1764113985.xml · nonDerivative · entry 3 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 23:39 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,500 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0002034679-25-000006 · wk-form4_1764113985.xml · derivative · entry 7 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,370 Underlying: Common Stock · 5,500 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · derivative.exercise_date: 25% of the shares underlying this option vested on July 24, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 23:39 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 5,500 | $18.45 | $101,475.00 |
DisclosureSEC source: 0002034679-25-000006 · wk-form4_1764113985.xml · nonDerivative · entry 2 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,497 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 23:39 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 5,500 | $3.79 | $20,843.90 |
DisclosureSEC source: 0002034679-25-000006 · wk-form4_1764113985.xml · nonDerivative · entry 1 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 21:23 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0002034679-25-000003 · wk-form4_1760131397.xml · derivative · entry 3 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,870 Underlying: Common Stock · 22,000 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · derivative.exercise_date: 25% of the shares underlying this option vested on July 24, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 21:23 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 22,000 | $18.45 | $405,900.00 |
DisclosureSEC source: 0002034679-25-000003 · wk-form4_1760131397.xml · nonDerivative · entry 2 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,497 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 21:23 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 22,000 | $3.79 | $83,375.60 |
DisclosureSEC source: 0002034679-25-000003 · wk-form4_1760131397.xml · nonDerivative · entry 1 Raben David · CIK 0002034679 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.